# Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

> **NCT04184921** · PHASE2 · COMPLETED · sponsor: **Daping Hospital and the Research Institute of Surgery of the Third Military Medical University** · enrollment: 216 (actual)

## Conditions studied

- Lung Cancer Non-small Cell Stage IV

## Interventions

- **DRUG:** Aspirin 100mg
- **DRUG:** Osimertinib 80 MG

## Key facts

- **NCT ID:** NCT04184921
- **Lead sponsor:** Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04184921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04184921, "Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04184921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*